Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.


Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
01 2021
Historique:
received: 30 11 2019
accepted: 18 11 2020
entrez: 8 1 2021
pubmed: 9 1 2021
medline: 11 2 2021
Statut: ppublish

Résumé

Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical studies and therapeutic testing. It has been proposed that the mouse host affects tumor evolution during PDX engraftment and propagation, affecting the accuracy of PDX modeling of human cancer. Here, we exhaustively analyze copy number alterations (CNAs) in 1,451 PDX and matched patient tumor (PT) samples from 509 PDX models. CNA inferences based on DNA sequencing and microarray data displayed substantially higher resolution and dynamic range than gene expression-based inferences, and they also showed strong CNA conservation from PTs through late-passage PDXs. CNA recurrence analysis of 130 colorectal and breast PT/PDX-early/PDX-late trios confirmed high-resolution CNA retention. We observed no significant enrichment of cancer-related genes in PDX-specific CNAs across models. Moreover, CNA differences between patient and PDX tumors were comparable to variations in multiregion samples within patients. Our study demonstrates the lack of systematic copy number evolution driven by the PDX mouse host.

Identifiants

pubmed: 33414553
doi: 10.1038/s41588-020-00750-6
pii: 10.1038/s41588-020-00750-6
pmc: PMC7808565
mid: NIHMS1648210
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-99

Subventions

Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/T001267/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U54 CA224065
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA010815
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA034196
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA114046
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224083
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211199
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA224067
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224070
Pays : United States

Investigateurs

Matthew H Bailey (MH)
Vito W Rebecca (VW)
Michael A Davies (MA)
Peter N Robinson (PN)
Brian J Sanderson (BJ)
Steven B Neuhauser (SB)
Lacey E Dobrolecki (LE)
Xiaofeng Zheng (X)
Mourad Majidi (M)
Ran Zhang (R)
Xiaoshan Zhang (X)
Argun Akcakanat (A)
Kurt W Evans (KW)
Timothy A Yap (TA)
Dali Li (D)
Erkan Yucan (E)
Christopher D Lanier (CD)
Turcin Saridogan (T)
Bryce P Kirby (BP)
Min Jin Ha (MJ)
Huiqin Chen (H)
Scott Kopetz (S)
David G Menter (DG)
Jianhua Zhang (J)
Shannon N Westin (SN)
Michael P Kim (MP)
Bingbing Dai (B)
Don L Gibbons (DL)
Coya Tapia (C)
Vanessa B Jensen (VB)
Gao Boning (G)
John D Minna (JD)
Hyunsil Park (H)
Brenda C Timmons (BC)
Luc Girard (L)
Dylan Fingerman (D)
Qin Liu (Q)
Rajasekharan Somasundaram (R)
Min Xiao (M)
Vashisht G Yennu-Nanda (VG)
Michael T Tetzlaff (MT)
Xiaowei Xu (X)
Katherine L Nathanson (KL)
Song Cao (S)
Feng Chen (F)
John F DiPersio (JF)
Kian H Lim (KH)
Cynthia X Ma (CX)
Fernanda M Rodriguez (FM)
Brian A Van Tine (BA)
Andrea Wang-Gillam (A)
Michael C Wendl (MC)
Yige Wu (Y)
Matthew A Wyczalkowski (MA)
Lijun Yao (L)
Reyka Jayasinghe (R)
Rebecca L Aft (RL)
Ryan C Fields (RC)
Jingqin Luo (J)
Katherine C Fuh (KC)
Vicki Chin (V)
John DiGiovanna (J)
Jeffrey Grover (J)
Soner Koc (S)
Sara Seepo (S)
Tiffany Wallace (T)
Chong-Xian Pan (CX)
Moon S Chen (MS)
Luis G Carvajal-Carmona (LG)
Amanda R Kirane (AR)
May Cho (M)
David R Gandara (DR)
Jonathan W Riess (JW)
Tiffany Le (T)
Ralph W deVere White (RW)
Clifford G Tepper (CG)
Hongyong Zhang (H)
Nicole B Coggins (NB)
Paul Lott (P)
Ana Estrada (A)
Ted Toal (T)
Alexa Morales Arana (AM)
Guadalupe Polanco-Echeverry (G)
Sienna Rocha (S)
Ai-Hong Ma (AH)
Nicholas Mitsiades (N)
Salma Kaochar (S)
Bert W O'Malley (BW)
Matthew J Ellis (MJ)
Susan G Hilsenbeck (SG)
Michael Ittmann (M)
Roebi de Bruijn (R)
Petra Ter Brugge (P)
Simona Corso (S)
Alessandro Fiori (A)
Silvia Giordano (S)
Marieke van de Ven (M)
Daniel S Peeper (DS)
Ian Miller (I)
Cristina Bernadó (C)
Beatriz Morancho (B)
Lorena Ramírez (L)
Joaquín Arribas (J)
Héctor G Palmer (HG)
Alejandro Piris-Gimenez (A)
Laura Soucek (L)
Ahmed Dahmani (A)
Elodie Montaudon (E)
Fariba Nemati (F)
Virginie Dangles-Marie (V)
Didier Decaudin (D)
Sergio Roman-Roman (S)
Denis G Alférez (DG)
Katherine Spence (K)
Robert B Clarke (RB)
Mohamed Bentires-Alj (M)
David K Chang (DK)
Andrew V Biankin (AV)
Alejandra Bruna (A)
Martin O'Reilly (M)
Carlos Caldas (C)
Oriol Casanovas (O)
Eva Gonzalez-Suarez (E)
Purificacíon Muñoz (P)
Alberto Villanueva (A)
Nathalie Conte (N)
Jeremy Mason (J)
Ross Thorne (R)
Terrence F Meehan (TF)
Helen Parkinson (H)
Zdenka Dudova (Z)
Ales Křenek (A)
Dalibor Stuchlík (D)
Olivier Elemento (O)
Giorgio Inghirami (G)
Anna Golebiewska (A)
Simone P Niclou (SP)
G Bea A Wisman (GBA)
Steven de Jong (S)
Petra Kralova (P)
Radislav Sedlacek (R)
Elisa Claeys (E)
Eleonora Leucci (E)
Massimiliano Borsani (M)
Luisa Lanfrancone (L)
Pier Giuseppe Pelicci (PG)
Gunhild Mari Mælandsmo (GM)
Jens Henrik Norum (JH)
Emilie Vinolo (E)

Commentaires et corrections

Type : ErratumIn

Références

Richmond, A. & Su, Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis. Models Mech. 1, 78–82 (2008).
Walrath, J. C., Hawes, J. J., Van Dyke, T. & Reilly, K. M. Genetically engineered mouse models in cancer research. Adv. Cancer Res. 106, 113–164 (2010).
pubmed: 20399958 pmcid: 3533445
Hait, W. N. Anticancer drug development: the grand challenges. Nat. Rev. Drug Discov. 9, 253–254 (2010).
pubmed: 20369394
Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118–130 (2007).
pubmed: 17259968
Brehm, M. A., Shultz, L. D. & Greiner, D. L. Humanized mouse models to study human diseases. Curr. Opin. Endocrinol. Diabetes Obes. 17, 120–125 (2010).
pubmed: 20150806 pmcid: 2892284
Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998–1013 (2014).
pubmed: 25185190 pmcid: 4167608
Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 254–268 (2017).
pubmed: 28104906
Bruna, A. et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 167, 260–274.e22 (2016).
pubmed: 27641504 pmcid: 5037319
Reyal, F. et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 14, R11 (2012).
pubmed: 22247967 pmcid: 3496128
Landis, M. D., Lehmann, B. D., Pietenpol, J. A. & Chang, J. C. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res. 15, 201 (2013).
pubmed: 23339383 pmcid: 3672825
DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514–1520 (2011).
pubmed: 22019887 pmcid: 3553601
Bankert, R. B. et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS ONE 6, e24420 (2011).
pubmed: 21935406 pmcid: 3174163
Julien, S. et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18, 5314–5328 (2012).
pubmed: 22825584
Lee, H. W. et al. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin. Cancer Res. 21, 1172–1182 (2015).
pubmed: 25549722
Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318–1325 (2015).
pubmed: 26479923
Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311–1316 (2011).
pubmed: 21673092 pmcid: 4629061
Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338–350 (2012).
pubmed: 22508028 pmcid: 3928688
Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422–426 (2014).
pubmed: 25470049 pmcid: 4864027
Cho, S.-Y. et al. Unstable genome and transcriptome dynamics during tumor metastasis contribute to therapeutic heterogeneity in colorectal cancers. Clin. Cancer Res. 25, 2821–2834 (2019).
pubmed: 30670495 pmcid: 7875093
Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999–1005 (2010).
pubmed: 20393555 pmcid: 2872544
Giessler, K. M. et al. Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. J. Exp. Med. 214, 2073–2088 (2017).
pubmed: 28572216 pmcid: 5502434
Sato, K. et al. Multiregion genomic analysis of serially transplanted patient-derived xenograft tumors. Cancer Genom. Proteom. 16, 21–27 (2019).
Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567–1575 (2017).
pubmed: 28991255 pmcid: 5659952
Kim, H. et al. High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts. Sci. Rep. 8, 17937 (2018).
pubmed: 30560892 pmcid: 6298990
Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116–1130 (2013).
pubmed: 24055055
He, S. et al. PDXliver: a database of liver cancer patient derived xenograft mouse models. BMC Cancer 18, 550 (2018).
pubmed: 29743053 pmcid: 5944069
Zare, F., Hosny, A. & Nabavi, S. Noise cancellation using total variation for copy number variation detection. BMC Bioinformatics 19, 361 (2018).
pubmed: 30343665 pmcid: 6196408
Wineinger, N. E. & Tiwari, H. K. The impact of errors in copy number variation detection algorithms on association results. PLoS ONE 7, e32396 (2012).
pubmed: 22523537 pmcid: 3327691
Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64–70 (2015).
pubmed: 25319062
Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).
pubmed: 27100738 pmcid: 4839673
Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013).
pubmed: 24071852 pmcid: 3966983
Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676–689.e3 (2018).
pubmed: 29622463 pmcid: 6028190
Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
pubmed: 20837533 pmcid: 2947907
Woo, X. Y. et al. Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines. BMC Med. Genet. 12, 92 (2019).
Evrard, Y. A. et al. Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis. Cancer Res. 80, 2286–2297 (2020).
pubmed: 32152150 pmcid: 7272270
Conway, T. et al. Xenome—a tool for classifying reads from xenograft samples. Bioinformatics 28, i172–i178 (2012).
pubmed: 22689758 pmcid: 3371868
Ben-David, U., Mayshar, Y. & Benvenisty, N. Virtual karyotyping of pluripotent stem cells on the basis of their global gene expression profiles. Nat. Protoc. 8, 989–997 (2013).
pubmed: 23619890
Ben-David, U. et al. The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. Nat. Commun. 7, 12160 (2016).
pubmed: 27374210 pmcid: 4932194
Motulsky, H. J. & Brown, R. E. Detecting outliers when fitting data with nonlinear regression—a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics 7, 123 (2006).
pubmed: 16526949 pmcid: 1472692
Sanchez-Vega, F. et al. Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 173, 321–337.e10 (2018).
pubmed: 29625050 pmcid: 6070353
Patterson, S. E. et al. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Hum. Genomics 10, 4 (2016).
pubmed: 26772741 pmcid: 4715272
Patterson, S. E., Statz, C. M., Yin, T. & Mockus, S. M. Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data. NPJ Precis. Oncol. 3, 2 (2019).
pubmed: 30675517 pmcid: 6333807
Sondka, Z. et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696–705 (2018).
pubmed: 30293088 pmcid: 6450507
The Cancer Genome Atlas Networket al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
pmcid: 3465532
The Cancer Genome Atlas Networket al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
The Cancer Genome Atlas Research Networket al. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
pmcid: 4231481
The Cancer Genome Atlas Research Networket al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).
pmcid: 3466113
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
pubmed: 22460905 pmcid: 3320027
Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503–508 (2019).
pubmed: 31068700 pmcid: 6697103
Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007–20012 (2007).
pubmed: 18077431 pmcid: 2148413
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
pubmed: 21527027 pmcid: 3218867
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102 pubmed: 16199517 pmcid: 1239896
Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
pubmed: 12808457
Jamal-Hanjani, M. et al. Tracking the evolution of non–small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
pubmed: 28445112
Ben-David, U., Beroukhim, R. & Golub, T. R. Genomic evolution of cancer models: perils and opportunities. Nat. Rev. Cancer 19, 97–109 (2019).
pubmed: 30578414 pmcid: 6493335
Mer, A. S. et al. Integrative pharmacogenomics analysis of patient-derived xenografts. Cancer Res. 79, 4539–4550 (2019).
pubmed: 31142512
Isella, C. et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47, 312–319 (2015).
pubmed: 25706627
Park, E. S. et al. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc. Natl Acad. Sci. USA 108, 17456–17461 (2011).
pubmed: 21987811 pmcid: 3198333
Liu, Y. et al. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Sci. Rep. 9, 6314 (2019).
pubmed: 31004097 pmcid: 6474864
Isella, C. et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat. Commun. 8, 15107 (2017).
pubmed: 28561063 pmcid: 5499209
Leary, R. J. et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl Acad. Sci. USA 105, 16224–16229 (2008).
pubmed: 18852474 pmcid: 2571022
Bierkens, M. et al. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer 52, 56–68 (2013).
pubmed: 22987659
Krijgsman, O., Carvalho, B., Meijer, G. A., Steenbergen, R. D. M. & Ylstra, B. Focal chromosomal copy number aberrations in cancer—needles in a genome haystack. Biochim. Biophys. Acta Mol. Cell Res. 1843, 2698–2704 (2014).
Bignell, G. R. et al. Signatures of mutation and selection in the cancer genome. Nature 463, 893–898 (2010).
pubmed: 20164919 pmcid: 3145113
De Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
pubmed: 25301630 pmcid: 4636050
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
pubmed: 24487277 pmcid: 4636053
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
pubmed: 22397650 pmcid: 4878653
Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
pubmed: 30894752 pmcid: 6954100
Schriml, L. M. et al. Human Disease Ontology 2018 update: classification, content and workflow expansion. Nucleic Acids Res. 47, D955–D962 (2018).
pmcid: 6323977
The Cancer Genome Atlas Networket al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015).
Abeshouse, A. et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950–965.e28 (2017).
pmcid: 5693358
Wang, K. et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 17, 1665–1674 (2007).
pubmed: 17921354 pmcid: 2045149
International HapMap Consortium The International HapMap Project. Nature 426, 789–796 (2003).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002
Scheinin, I. et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 24, 2022–2032 (2014).
pubmed: 25236618 pmcid: 4248318
Desmedt, C. et al. Uncovering the genomic heterogeneity of multifocal breast cancer. J. Pathol. 236, 457–466 (2015).
pubmed: 25850943 pmcid: 4691324
Weissbein, U., Schachter, M., Egli, D. & Benvenisty, N. Analysis of chromosomal aberrations and recombination by allelic bias in RNA-Seq. Nat. Commun. 7, 12144 (2016).
pubmed: 27385103 pmcid: 4941052
Lingjaerde, O. C., Baumbusch, L. O., Liestol, K., Glad, I. K. & Borresen-Dale, A. L. CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics 21, 821–822 (2005).
pubmed: 15531610
Redon, R. et al. Global variation in copy number in the human genome. Nature 444, 444–454 (2006).
pubmed: 17122850 pmcid: 2669898
Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178–192 (2013).
pubmed: 22517427
Skidmore, Z. L. et al. GenVisR: genomic visualizations in R. Bioinformatics 32, 3012–3014 (2016).
pubmed: 27288499 pmcid: 5039916
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
pubmed: 20110278 pmcid: 2832824
Zhang, X. M. et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 73, 4885–4897 (2013).
pubmed: 23737486 pmcid: 3732575
Coussy, F. et al. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. Int. J. Cancer 145, 1902–1912 (2019).
pubmed: 30859564
Riaz, N. et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat. Commun. 8, 857 (2017).
pubmed: 29021619 pmcid: 5636842
Adams, D. J. et al. NAMPT is the cellular target of STF-31-like small-molecule probes. ACS Chem. Biol. 9, 2247–2254 (2014).
pubmed: 25058389 pmcid: 4201331
Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453–457 (2017).
pubmed: 28678785 pmcid: 5667900
Stransky, N. et al. Pharmacogenomic agreement between two cancer cell line data sets. Nature 528, 84–87 (2015).
pmcid: 6343827
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
pubmed: 21546393 pmcid: 3106198
Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969

Auteurs

Xing Yi Woo (XY)

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

Jessica Giordano (J)

Department of Oncology, University of Turin, Turin, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Anuj Srivastava (A)

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

Zi-Ming Zhao (ZM)

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

Michael W Lloyd (MW)

The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.

Roebi de Bruijn (R)

Netherlands Cancer Institute, Amsterdam, the Netherlands.

Yun-Suhk Suh (YS)

College of Medicine, Seoul National University, Seoul, Republic of Korea.

Rajesh Patidar (R)

Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Li Chen (L)

Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Sandra Scherer (S)

Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Matthew H Bailey (MH)

Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Department of Human Genetics, University of Utah, Salt Lake City, UT, USA.

Chieh-Hsiang Yang (CH)

Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Emilio Cortes-Sanchez (E)

Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Yuanxin Xi (Y)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jing Wang (J)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jayamanna Wickramasinghe (J)

The Wistar Institute, Philadelphia, PA, USA.

Andrew V Kossenkov (AV)

The Wistar Institute, Philadelphia, PA, USA.

Vito W Rebecca (VW)

The Wistar Institute, Philadelphia, PA, USA.

Hua Sun (H)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

R Jay Mashl (RJ)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

Sherri R Davies (SR)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

Ryan Jeon (R)

Seven Bridges Genomics, Charlestown, MA, USA.

Christian Frech (C)

Seven Bridges Genomics, Charlestown, MA, USA.

Jelena Randjelovic (J)

Seven Bridges Genomics, Charlestown, MA, USA.

Jacqueline Rosains (J)

Seven Bridges Genomics, Charlestown, MA, USA.

Francesco Galimi (F)

Department of Oncology, University of Turin, Turin, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Andrea Bertotti (A)

Department of Oncology, University of Turin, Turin, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Adam Lafferty (A)

Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

Alice C O'Farrell (AC)

Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

Elodie Modave (E)

Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Diether Lambrechts (D)

Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Petra Ter Brugge (P)

Netherlands Cancer Institute, Amsterdam, the Netherlands.

Violeta Serra (V)

Vall d´Hebron Institute of Oncology, Barcelona, Spain.

Elisabetta Marangoni (E)

Department of Translational Research, Institut Curie, PSL Research University, Paris, France.

Rania El Botty (R)

Department of Translational Research, Institut Curie, PSL Research University, Paris, France.

Hyunsoo Kim (H)

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

Jong-Il Kim (JI)

College of Medicine, Seoul National University, Seoul, Republic of Korea.

Han-Kwang Yang (HK)

College of Medicine, Seoul National University, Seoul, Republic of Korea.

Charles Lee (C)

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Department of Life Sciences, Ewha Womans University, Seoul, Republic of Korea.

Dennis A Dean (DA)

Seven Bridges Genomics, Charlestown, MA, USA.

Brandi Davis-Dusenbery (B)

Seven Bridges Genomics, Charlestown, MA, USA.

Yvonne A Evrard (YA)

Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

James H Doroshow (JH)

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.

Alana L Welm (AL)

Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Bryan E Welm (BE)

Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Michael T Lewis (MT)

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.

Bingliang Fang (B)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jack A Roth (JA)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funda Meric-Bernstam (F)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Meenhard Herlyn (M)

The Wistar Institute, Philadelphia, PA, USA.

Michael A Davies (MA)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Li Ding (L)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

Shunqiang Li (S)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

Ramaswamy Govindan (R)

Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

Claudio Isella (C)

Department of Oncology, University of Turin, Turin, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Jeffrey A Moscow (JA)

Investigational Drug Branch, National Cancer Institute, Bethesda, MD, USA.

Livio Trusolino (L)

Department of Oncology, University of Turin, Turin, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Annette T Byrne (AT)

Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

Jos Jonkers (J)

Netherlands Cancer Institute, Amsterdam, the Netherlands.

Carol J Bult (CJ)

The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.

Enzo Medico (E)

Department of Oncology, University of Turin, Turin, Italy. enzo.medico@unito.it.
Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy. enzo.medico@unito.it.

Jeffrey H Chuang (JH)

The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. jeff.chuang@jax.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH